Foveal LLP Independent Investment Research Foveal Research

Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was...

Head and neck specific? The FDA placed a partial clinical trial hold on recruiting new patients to AstraZeneca’s anti PD-L1 (durvalumab)...

Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears New ESMO lung cancer data bodes well...

Astra's underappreciated oncology pipeline stalking the market We initiate on AstraZeneca with an overweight rating and a Target Price of...

Pressure on anti PD-L1s: ESMO 2016 increases the body of evidence that anti PD-L1s from Roche, Astra and PFE/MRCG may fall short of PD-1s...

PD1 market continues to shrink, but Bristol’s failure not good news for rivals BMY announced Friday that its pivotal phase III study of...

Pressure on consensus: We have long argued all IO competitors will have to better Bristol’s Opdivo + Yervoy combination in the biggest...

New ASCO 2016 data continues to support lower than consensus potential revenues, modest anti PD-L1 efficacy and more doubts over chemo...

Too little too late Roche today announced that the FDA accepted its filing for atezolizumab in 2nd line PD‑L1 +ve Non-Small cell lung...

Anti PD-1 commercial potential still appears vastly overestimated With PD-1 checkpoint inhibition clearly set to improve the landscape of...